NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDVemurafenib Zelboraf® Malignant disease and immunosuppression, Protein kinase inhibitors, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Vemurafenib Vemurafenib [Specialist Drug] Malignant Disease, Targeted Therapy Responsive Malignancy, Antineoplastic Drugs Protein Kinase Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA Drug Safety Update (November 2015) - Vemurafenib (Zelboraf▼): risk of potentiation of radiation toxicity
NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib